Q1 Earnings Estimate for CAPR Issued By HC Wainwright

Capricor Therapeutics Inc (NASDAQ:CAPR) – Equities research analysts at HC Wainwright issued their Q1 2025 earnings per share (EPS) estimates for shares of Capricor Therapeutics in a report issued on Thursday, March 20th. HC Wainwright analyst J. Pantginis anticipates that the biotechnology company will earn ($0.35) per share for the quarter. HC Wainwright currently has a “Buy” rating and a $77.00 price target on the stock. The consensus estimate for Capricor Therapeutics’ current full-year earnings is ($1.21) per share. HC Wainwright also issued estimates for Capricor Therapeutics’ Q3 2025 earnings at $0.94 EPS, Q4 2025 earnings at ($0.39) EPS, FY2025 earnings at $0.15 EPS and FY2026 earnings at ($0.61) EPS.

Capricor Therapeutics (NASDAQ:CAPR) last posted its quarterly earnings results on Wednesday, March 19th. The biotechnology company reported ($0.16) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.31) by $0.15. The company had revenue of $11.13 million for the quarter, compared to the consensus estimate of $9.87 million. Capricor Therapeutics had a negative net margin of 146.86% and a negative return on equity of 112.95%.

Separately, Cantor Fitzgerald reiterated an “overweight” rating and set a $30.00 price target on shares of Capricor Therapeutics in a report on Thursday, March 20th. One equities research analyst has rated the stock with a sell rating and six have assigned a buy rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $34.50.

Capricor Therapeutics Price Performance

Shares of NASDAQ:CAPR opened at $13.48 on Monday. Capricor Therapeutics has a one year low of $3.52 and a one year high of $23.40. The company has a market cap of $612.94 million, a price-to-earnings ratio of -12.72 and a beta of 4.10. The firm has a 50 day simple moving average of $14.09 and a 200 day simple moving average of $14.83.

Institutional Investors Weigh In On Capricor Therapeutics

Institutional investors have recently made changes to their positions in the stock. Vanguard Group Inc. increased its position in Capricor Therapeutics by 44.4% during the 4th quarter. Vanguard Group Inc. now owns 2,276,784 shares of the biotechnology company’s stock valued at $31,420,000 after purchasing an additional 700,243 shares during the period. Farallon Capital Management LLC acquired a new stake in shares of Capricor Therapeutics during the fourth quarter worth $31,056,000. Geode Capital Management LLC raised its stake in Capricor Therapeutics by 37.8% during the fourth quarter. Geode Capital Management LLC now owns 879,468 shares of the biotechnology company’s stock worth $12,139,000 after buying an additional 241,279 shares during the last quarter. Altium Capital Management LLC raised its stake in Capricor Therapeutics by 150.5% during the fourth quarter. Altium Capital Management LLC now owns 714,000 shares of the biotechnology company’s stock worth $9,853,000 after buying an additional 429,000 shares during the last quarter. Finally, Woodline Partners LP acquired a new position in Capricor Therapeutics in the fourth quarter valued at $8,693,000. Institutional investors own 21.68% of the company’s stock.

About Capricor Therapeutics

Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.